Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment

Jong, F.C. De; Laajala, T.D.; Hoedemaeker, R.F.; Rinaldetti, S.; Jordan, K.; Madè, Alexandra; Nieuwkamer, B.; Boevé, E.R.; Janssen, E.A.M.; Mahmoudi, T.; Boormans, J.L.; Theodorescu, D.; Costello, J.C.; Zuiverloon, T.C.M.

doi:10.1016/s0302-2838(22)00156-7

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These efforts have provided important prognostic information compared to clinical characteristics. This approach was recently extended in a study of patients with high-risk NMI treated with Bacillus Calmette-Guérin (BCG) to define three molecular subtypes that were predictive of BCG treatment response [51]. In MI bladder cancer, tumor profiling is also being evaluated to guide the selection of individualized neoadjuvant or adjuvant chemo- or immunotherapy [52 ▪▪ ].…”

Section: Introductionmentioning

confidence: 99%

Use of genomic markers to improve epidemiologic and clinical research in urology

Cancel-Tassin,

Koutros

2023

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review Urologic cancers result from the appearance of genomic alterations in the target organ due to the combination of genetic and environmental factors. Knowledge of the genomic markers involved in their etiology and mechanisms for their development continue to progress. This reviewed provides an update on recent genomic studies that have informed epidemiologic and clinical research in urology. Recent findings Inherited variations are an established risk factor for urologic cancers with significant estimates of heritability for prostate, kidney, and bladder cancer. The roles of both rare germline variants, identified from family-based studies, and common variants, identified from genome-wide association studies, have provided important information about the genetic architecture for urologic cancers. Large-scale analyses of tumors have generated genomic, epigenomic, transcriptomic, and proteomic data that have also provided novel insights into etiology and mechanisms. These tumors characteristics, along with the associated tumor microenvironment, have attempted to provide more accurate risk stratification, prognosis of disease and therapeutic management. Summary Genomic studies of inherited and acquired variation are changing the landscape of our understanding of the causes of urologic cancers and providing important translational insights for their management. Their use in epidemiologic and clinical studies is thus essential.

show abstract

Section: Introductionmentioning

confidence: 99%

Use of genomic markers to improve epidemiologic and clinical research in urology

Cancel-Tassin,

Koutros

2023

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

“…Jong et al recently described three molecular subtypes of HR NMIBC characterizing innate BCG-responsiveness. 4 A comprehensive phenotypic system such as this will be paramount to help providers navigate our ever-expanding catalog of therapeutic options and route patients toward the most efficacious first-line treatment option.…”

mentioning

confidence: 99%

Editorial Comment

Bharadwaj,

Koehne

2024

Journal of Urology

View full text Add to dashboard Cite

Non-muscle invasive bladder cancer subtypes with differential response to intravesical bacillus Calmette-Guerin treatment

Cited by 2 publications

References 0 publications

Use of genomic markers to improve epidemiologic and clinical research in urology

Use of genomic markers to improve epidemiologic and clinical research in urology

Editorial Comment

Contact Info

Product

Resources

About